zintick

Karyopharm Therapeutics KPTI

Karyopharm Therapeutics Inc. · Nasdaq · Pharmaceutical Preparations

$0.66-24.77%close on Oct. 30, 2026 · volume 3.4M · Yahoo Finance

Price, last 49 sessions

$0.50$1.00$1.50$2.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 30, 2026 · high $2.06 · low $0.32 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 16, 2026Kristin Abate
Chief Accounting Officer
Sold4,788$0.34$1,647
Oct. 1, 2026Kristin Abate
Chief Accounting Officer
Sold378$1.19$450
Sept. 1, 2026Kristin Abate
Chief Accounting Officer
Sold19$2.02$38
July 28, 2026Stuart Poulton
EVP, Chief Development Officer
Sold189$7.10$1,342

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 23 →
  • 8-KNov. 2, 2026, 9:21 a.m. ETView on SEC.govOur explainer

    Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedKaryopharm Therapeutics Files Chapter 11 and Signs Restructuring Support Agreement for Merger with Ayrmid; Common Stock Expected to Have No Value

  • SCHEDULE 13G/AOct. 28, 2026, 5:34 p.m. ETView on SEC.gov
  • 8-KOct. 22, 2026, 4:15 p.m. ETView on SEC.gov

    Other events

    AI summary, unreviewedKaryopharm Therapeutics extends forbearance period on indentures to November 1, 2026

  • 4Oct. 19, 2026, 4:03 p.m. ETView on SEC.gov
  • 8-KOct. 14, 2026, 7:30 a.m. ETView on SEC.gov

    Other events

    AI summary, unreviewedKaryopharm Therapeutics extends forbearance period on indentures to October 22, 2026

  • SCHEDULE 13G/AOct. 8, 2026, 10:26 a.m. ETView on SEC.gov
  • 4Oct. 2, 2026, 4:01 p.m. ETView on SEC.gov
  • SCHEDULE 13G/ASept. 25, 2026, 2:18 p.m. ETView on SEC.gov